91182-86-4

Basic information

• Product Name: Methyl 2-(6-chloro-1H-indol-3-yl)-2-oxoacetate
• Synonyms: Methyl 2-(6-chloro-1H-indol-3-yl)-2-oxoacetate;2-(6-Chloro-1H-indol-3-yl)-2-oxoacetic acid methyl ester;1H-INDOLE-3-ACETIC ACID, 6-CHLORO-α-OXO-, METHYL ESTER
• CAS NO: 91182-86-4
• Molecular Formula: C11H8ClNO3
• Molecular Weight: 237.63912
• Mol File: 91182-86-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 273-275℃ (acetone )
• Appearance: /
• CAS DataBase Reference: Methyl 2-(6-chloro-1H-indol-3-yl)-2-oxoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(6-chloro-1H-indol-3-yl)-2-oxoacetate(91182-86-4)
• EPA Substance Registry System: Methyl 2-(6-chloro-1H-indol-3-yl)-2-oxoacetate(91182-86-4)

Safety Data

• Hazardous Substances Data: 91182-86-4(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 17422-33-2 6-chloroindole 
• 527-31-1 hexaketocyclohexane 
• 252979-02-5 2-(6-chloro-1H-indol-3-yl)-2-oxoacetyl chloride 
• 79-37-8 oxalyl dichloride 
• 124-41-4 sodium methylate 

Relevant articles and documents

Copper-catalyzed carbonylative transformations of indoles with hexaketocyclohexane

With hexaketocyclohexane octahydrate as the carbon monoxide source, a novel procedure for copper-catalyzed direct double carbonylation of indoles has been established. Using alcohols as reaction partners, moderate to good yields of the desired double carbonylation products have been obtained. Wide functional group tolerance and substrate scope can be observed.

3 - (1, 2, 4 - triazole [4, 3 - a] pyridine - 3 - yl) - 4 - (1H - Indol - 3 - yl) maleimide derivatives and its preparation method and application

The invention provides a 3-(1,2,4-triazolo(4,3-a)pyridine-3-yl)-4-(1H-indole-3-yl)maleimide derivative with a novel structure and a preparation method and application of the derivative. The compound can be used for treating ischemic cerebral apoplexy. The general structural formula of the compound is shown in the specification.

Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3β Inhibitors and Anti-Ischemic Agents

A series of novel 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides were designed, synthesized, and biologically evaluated for their GSK-3β inhibitory activities. Most compounds showed favorable inhibitory activities against GSK-3β protein. Among them, compounds 5n, 5o, and 5p significantly reduced GSK-3β substrate tau phosphorylation at Ser396 in primary neurons, indicating inhibition of cellular GSK-3β activity. In the in vitro neuronal injury models, compounds 5n, 5o, and 5p prevented neuronal death against glutamate, oxygen-glucose deprivation, and nutrient serum deprivation which are closely associated with cerebral ischemic stroke. In the in vivo cerebral ischemia animal model, compound 5o reduced infarct size by 10% and improved the neurological deficit. The results may provide new insights into the development of novel GSK-3β inhibitors with potential neuroprotective activity against brain ischemic stroke.